AlphaCentric Advisors’s Sarepta Therapeutics SRPT Stock Holding History

AlphaCentric Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$269K	Sell	2,211 -15,789	-88%	-$1.93M	0.27%	97
2024 Q3	$2.25M	Buy	18,000 +10,500	+140%	+$1.45M	1.67%	12
2024 Q2	$1.19M	Buy	7,500 +7,231	+2,688%	+$929K	0.87%	39
2024 Q1	$34.8K	Sell	269 -36	-12%	-$4.41K	0.02%	223
2023 Q4	$29.4K	Sell	305 -31	-9%	-$2.97K	0.02%	211
2023 Q3	$40.7K	Sell	336 -57	-15%	-$6.44K	0.02%	224
2023 Q2	$45K	Buy	+393	New	+$50.7K	0.03%	229
2021 Q4	$540K	Sell	6,000 -3,000	-33%	-$256K	0.16%	60
2021 Q3	$832K	Sell	9,000 -5,000	-36%	-$385K	0.21%	41
2021 Q2	$1.09M	Buy	14,000 +4,500	+47%	+$341K	0.3%	19
2021 Q1	$708K	Buy	9,500 +8,775	+1,210%	+$810K	0.24%	33
2020 Q4	$124K	Buy	725 +550	+314%	+$81.5K	0.05%	101
2020 Q3	$25K	Buy	+175	New	+$26.6K	0.01%	137

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AlphaCentric Advisors's SRPT Position: Q4 2024 in Review

AlphaCentric Advisors reduced its Sarepta Therapeutics (SRPT) stake by 88% in Q4 2024, selling an estimated $1.93M and leaving 2,211 shares worth $269K. The position accounts for 0.27% of the portfolio, ranked #97.

AlphaCentric Advisors first reported a position in SRPT in Q3 2020 and has held it in 13 quarters since. The position peaked at $2.25M in Q3 2024. 464 funds tracked by Wall St. Rank hold SRPT as of Q4 2024.

AlphaCentric Advisors held 2,211 shares of Sarepta Therapeutics worth $269K as of Q4 2024.
AlphaCentric Advisors sold 15,789 Sarepta Therapeutics shares in Q4 2024, an estimated $1.93M.
Sarepta Therapeutics made up 0.27% of AlphaCentric Advisors's portfolio in Q4 2024, its #97 holding.
AlphaCentric Advisors first reported a position in Sarepta Therapeutics in Q3 2020 and has held it in 13 quarters since.
AlphaCentric Advisors's Sarepta Therapeutics position peaked at $2.25M in Q3 2024.
464 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2024.

Based on AlphaCentric Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.